SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as traders closely watch the stock's relative strength and consolidation patterns amid a broader market pullback. Market participants are actively discussing the impact of recent subscription price increases on revenue growth while monitoring key technical resistance levels that could trigger a potential breakout.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is currently trending following news that it has secured FDA approval for VYKAT XR, the first therapy developed to treat hyperphagia in Prader-Willi syndrome. The community is actively discussing the stock's significant price momentum, debating the potential for a future acquisition by a larger pharmaceutical player, and evaluating the long-term commercial execution of this newly approved asset.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining significant momentum as the community rallies around 4/20-related catalysts and expectations of broader regulatory shifts in the cannabis industry. The project is being highlighted for its focus on organic growth and culture-driven engagement, with supporters pointing to its low market cap and potential for long-term viability as key drivers of interest.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

Neurocrine Biosciences is trending due to a definitive agreement to acquire Soleno Therapeutics for $53 per share in an all-cash deal valued at approximately $2.9 billion. Community sentiment is mixed, with some investors debating the valuation and strategic rationale of the acquisition, while others are pressuring management to accelerate pipeline development or consider selling the company to unlock shareholder value.

“Buttcoin - The Next Bitcoin” is the memecoin version of Bitcoin. Launched on January 30, 2025, on Pump.fun, it’s a community-owned memecoin on Solana. The idea was inspired by a 4:20 minutes long YouTube video from 2013 called "The Next Bitcoin?" by James D. McMurray.

The Next Bitcoin

Investors are rallying behind $BUTTCOIN as a satirical movement aimed at disrupting the traditional financial system, with community members actively promoting it as the next major meme cycle. The conversation is driven by intense speculation and viral narratives, with supporters urging others to join the movement to flip Bitcoin while others emphasize the coin's role as a lighthearted commentary on market volatility.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

The AIRCOIN community is generating significant momentum on social platforms, emphasizing their long-term conviction and voluntary supply locking through AirLock to combat typical meme coin volatility. Investors are actively highlighting the project's multi-month development and resilient holder base as key differentiators in the broader Solana ecosystem.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Fremont, CA.

Seagate Technology Holdings Plc

Seagate Technology is trending as investors and analysts aggressively re-rate the storage sector, with recent high-conviction institutional initiations and price target hikes fueling excitement over sustained hyperscaler demand. While some in the community debate if the recent rally reflects a structural shift or an overextended valuation, the broader conversation remains focused on the company's critical role in the long-term AI infrastructure buildout.

Investment Managers Series Trust II - Tradr 2X Short NBIS Daily ETF

Tradr 2X Short NBIS Daily ETF

Traders are utilizing this 2X inverse ETF as a tactical tool to bet against Nebius, citing concerns over the company's widening losses and revenue performance. The community remains divided, with some viewing it as a high-conviction play on a potential AI sector correction, while others caution against the inherent risks of leveraged volatility.

Satellogic, Inc. operates as a vertically integrated geospatial company. It is creating and continuously enhancing the first scalable, fully automated EO platform with the ability to remap the entire planet at both high-frequency and high-resolution, providing accessible and affordable solutions for customers. The company was founded by Emiliano Kargieman and Gerardo Richarte in July 2010 and is headquartered in Davidson, NC.

Satellogic Inc - Ordinary Shares - Class A

Satellogic is gaining momentum as investors pivot toward the space sector following positive contract expansion news with the U.S. Naval Research Laboratory and growing anticipation for the upcoming SpaceX IPO. The community is actively debating the stock's long-term potential as a 'space-as-a-service' play, with many users focusing on technical setups and insider accumulation while others weigh the risks of dilution.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing significant market buzz and bullish momentum driven by the anticipation of a potential SpaceX IPO and the upcoming BlueBird satellite launch, which investors view as major catalysts for the broader space connectivity sector. The community is heavily focused on the stock's role in the direct-to-device satellite market, with many bulls maintaining high conviction in long-term infrastructure potential despite the ongoing volatility and mixed signals from short-sellers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>According to a report, AIG’s competitor, Chubb, approached the firm with an informal offer to acquire it; however, both Chubb and AIG denied the reports.</li><li>Citi maintained its ‘Neutral’ rating on AIG and assigned an $85 price target.</li><li>Piper Sandler raised its price target on the stock to $95 from $88 and maintained an ‘Overweight’ rating.</li></ul>American International Group (<a href="https://stocktwits.com/symbol/AIG">AIG</a>) stock drew investor attention on Monday after Citi analysts noted that merging with another large insurer would not benefit AIG.According to TheFly, Citi analysts wrote in a research note that they expect American International Group (AIG) to continue acquiring more firms rather than being acquired. Citi believes integration and revenue dyssynergies would likely overwhelm any potential cost savings from a large-scale transaction. The firm maintained a ‘Neutral’ rating on the shares, with an $85 price target.Earlier in the month, an Insurance Insider US <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.insuranceinsiderus.com/article/2fpahsm5la3on7eapsfsw/all-topics/m-a/chubb-made-informal-takeover-approach-for-aig?zephr_sso_ott=LTYHsi">report</a> indicated that Chubb had approached AIG with an informal acquisition offer. However, both firms have reportedly <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.insurancenews.com.au/international/aig-not-for-sale-amid-reports-of-rival-s-interest">denied</a> the same, according to Insurance News.&nbsp;In another note, Piper Sandler raised its price target on AIG to $95 from $88 and maintained an Overweight rating. The firm expects favorable weather to mean most insurers will report strong or even stronger-than-expected results, but pricing commentary will likely be more pessimistic.<h2 class="st-heading-2">Expansion Amidst Streamlining Operations</h2>AIG’s CEO, Peter Zaffino, has been streamlining its operations since taking the reins in 2021 by selling its global personal travel business, and continues to make acquisitions and investments to make AIG into a more capital-aligned company.AIG recently announced it will invest around $5 billion in specialty insurer Convex and asset manager Onex Corporation. As part of the deal, AIG acquired a 35% stake in Convex for $2.1 billion. It also said it will acquire a 9.9% ownership stake in asset manager Onex for about $646 million and will also invest up to $2 billion in its investment funds.AIG also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.everestglobal.com/news/news-details/2025/Everest-Announces-Agreement-to-Sell-Retail-Commercial-Insurance-Renewal-Rights-to-AIG/default.aspx">acquired</a> renewal rights to Everest Group’s global retail insurance portfolio for about $2 billion, which will allow AIG to grow its general insurance arm by incorporating Everest’s existing customers.<h2 class="st-heading-2">How Did Stoctwits Users React?</h2>Retail sentiment around AIG trended in “bearish” territory amid “high” message volumes.<figure class="image"><img style="aspect-ratio:633/74;" src="https://news.stocktwits-cdn.com/AIG_PNG_22be5e3e02.webp" alt="Retail sentiment around AIG trended in “bearish” territory amid “high” message volumes" width="633" height="74"></figure>Shares of AIG have surged over 10% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

The AIG (American International Group) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Does Citi Believe AIG Is More Likely To ‘Acquire’ Than Be Acquired?

Citi analysts believe integration and revenue dyssynergies would likely overwhelm any potential cost savings from a large-scale transaction.

Equity

Citi analysts believe integration and revenue dyssynergies would likely overwhelm any potential cost savings from a large-scale transaction.


Boston Scientific Corporation (BSX) said on Friday that it has entered into a definitive agreement to acquire privately held medical technology company Nalu Medical for an upfront cash payment of approximately $533 million for equity not currently owned by the company.Nalu is developing minimally invasive solutions for patients with chronic pain, and Boston Scientific has been a strategic investor in the company since 2017.The transaction is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/boston-scientific-announces-agreement-to-acquire-nalu-medical-inc-302587495.html">expected</a> to be completed in the first half of 2026, subject to the satisfaction of customary closing conditions. The transaction is not expected to impact Boston Scientific’s adjusted earnings per share (EPS) in 2026. However, the company expects it to be slightly accretive to adjusted EPS in 2027 and increasingly accretive thereafter.BSX shares traded down 1% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BSX">BSX stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.The acquisition is intended to expand the neuromodulation offerings for people living with chronic pain, Boston Scientific said."Adding the highly differentiated Nalu Medical technology complements our existing therapies—including spinal cord stimulation, basivertebral nerve ablation and radiofrequency ablation—enabling us to deliver advanced pain relief options to a wider variety of patient populations," President Jim Cassidy said.Nalu is expected to generate sales of more than $60 million in 2025 and to deliver year-over-year growth of over 25% in 2026.BSX stock is up by 9% this year and by about 13% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-falls-below-105-000-pulling-mstr-stock-lower-xrp-and-solana-drop/ch6sexmR383">Bitcoin Falls Below $105,000, Pulling MSTR Lower – XRP And Solana Drop Amid Banking Jitters</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A general view of a Boston Scientific advertisement during a women's college lacrosse game between the Notre Dame Fighting Irish and the Boston College Eagles on March 16, 2024. (Photo by Erica Denhoff/Icon Sportswire via Getty Images)

Boston Scientific To Acquire Privately-Held Pain Solutions Developer Nalu Medical For About $533M

Nalu Medical is developing minimally invasive solutions for patients with chronic pain, and Boston Scientific has been a strategic investor in the company since 2017.

Three varieties of McCormick spices in plastic table shaker containers. Salt free all purpose, garlic and herb and Perfect Pinch salt free garlic and herb. Variety of prepared and mixed Seasonings to add to any food dish.

McCormick CEO Flags Rising Prices On Global Trade Pressures: ‘Expect To Offset Rising Commodity Costs And Tariffs As Much As We Can’

McCormick now expects annual adjusted profit to be between $3 and $3.05 per share, compared with its previous estimate of $3.03 to $3.08 per share.

Med-tech company Medtronic (MDT) announced on Tuesday that its board of directors has appointed industry veterans John Groetelaars and Bill Jellison as independent directors, effective immediately, after Elliott Investment Management added a substantial stake in the firm.The company also announced the formation of two special committees. Of this, one will be responsible for guiding the evaluation and execution of growth-accretive tuck-in mergers and acquisitions, organic research and development investments, and potential divestitures.The other committee will align governance with the company's initiatives to optimize operational performance, deliver margin expansion, and drive sustained earnings acceleration, the company said.CEO Geoff Martha will serve as Chair of both of the newly formed committees, and both the newly appointed directors will serve on one or both of the committees. Groetelaars and Jellison will further be nominated to stand for election to the board at Medtronic's 2025 annual general meeting of shareholders, it <a target="_blank" rel="noopener noreferrer nofollow" href="https://news.medtronic.com/2025-08-19-Medtronic-announces-Board-appointments-and-shareholder-value-creation-initiatives-to-advance-strategic-priorities">said</a>.The company said that the move followed dialogue with Elliott Investment Management L.P., which is now one of the largest investors in the company. Elliott Partner Marc Steinberg stated that the decision to become one of the largest investors in Medtronic was driven by the conviction that the company is entering a new chapter of value creation.“We believe Medtronic's recent innovations in some of the medical technology sector's most attractive markets have positioned the company for an inflection in organic growth… Today's announcements – including the addition of new directors with deep medical technology experience and the formation of two focused Board committees – are the right steps towards realizing Medtronic's potential,” Steinberg said.The Wall Street Journal reported the board appointments earlier today. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MDT">MDT</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_19_at_7_52_05_AM_png_5d5cc8d38a.webp" alt="MDT's Sentiment Meter and Message Volume as of 7:50 a.m. ET on Aug. 19, 2025 | Source: Stocktwits" width="627" height="62"><figcaption>MDT's Sentiment Meter and Message Volume as of 7:50 a.m. ET on Aug. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes the company’s long-term value looks solid, if it can maintain steady revenue growth and keep innovating in key product lines.<stembedurl>https://stocktwits.com/JasonInsightMarkets/message/625725317</stembedurl>On Tuesday, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://news.medtronic.com/2025-08-19-Medtronic-reports-first-quarter-fiscal-2026-financial-results">reported</a> earnings for the first quarter of fiscal year 2026 (FY26), which ended July 25, and raised its FY26 earnings guidance. For FY26, the company continues to expect organic revenue growth of approximately 5%. It also raised its FY26 diluted and adjusted earnings per share guidance to the new range of $5.60 to $5.66 versus the prior range of $5.50 to $5.60.For the first quarter, the firm reported revenue of $8.578 billion, exceeding a Wall Street estimate of $8.371 billion. The growth was spurred by growth across the company’s cardiovascular, neuroscience, medical surgical, and diabetes business portfolios.Adjusted and diluted earnings per share in the quarter came in at $1.26, above an estimated $1.23.MDT stock is up by 16% this year and by about 9% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-readying-new-blackwell-based-b30-a-chip-for-china-as-us-tensions-flare-report/chsgO5iRdg9">Nvidia Readying New Blackwell-Based B30A Chip For China As US Tensions Flare: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Medtronic logo is displayed on a smartphone screen in front of a stock chart showcasing Medtronic's financial performance. (Photo by Cheng Xin/Getty Images)

Medtronic Appoints New Directors After Elliott Becomes Major Investor: Company Hikes FY26 Guidance After Q1 Beat

Elliott Partner Marc Steinberg stated that the decision to become one of the largest investors in Medtronic was driven by the conviction that the company is entering a new chapter of value creation. 

Analysts are optimistic about Medtronic (MDT) after the Centers for Medicare and Medicaid Services (CMS) proposed to cover renal denervation for uncontrolled hypertension.CMS on Thursday posted its proposed decision memo, stating that it proposes to cover radiofrequency renal denervation and ultrasound renal denervation for uncontrolled hypertension. The agency is now seeking comments on its proposed decision, and a final decision is expected by October 8.Renal denervation (RDN) is a new technology that uses catheters placed into the renal (kidney) arteries to ablate, or destroy, the renal sympathetic nerves to reduce blood pressure. RDN is intended to complement medications and lifestyle changes in patients with uncontrolled hypertension.Hypertension can lead to serious problems such as heart attack and stroke, the agency noted.Medtronic, the medical technology provider, has an RDN system called Symplicity Spyral, which was granted FDA premarket approval in November 2023. The system disrupts the overactive sympathetic signaling between the kidneys and brain to reduce blood pressure.<a href="https://stocktwits.com/symbol/MDT">MDT shares </a>were trading 1% higher at the time of writing.&nbsp;Several analysts reacted to the news:<ul style="list-style-type:square;"><li>Stifel maintains a ‘Hold’ rating and $87 price target on Medtronic shares. The Centers for Medicare &amp; Medicaid Services' initial proposal for renal denervation reimbursement "seems positive," the firm noted.</li><li>JPMorgan, meanwhile, keeps a ‘Neutral’ rating on Medtronic. JPMorgan told investors in a research note that there is no arguing that a broad national coverage decision for renal denervation is a win for Medtronic. This will enable the company to begin targeting the potentially multi-billion-dollar opportunity once the final rule is released in October, according to the analyst. However, JPMorgan believes it will "take some time to get there" as the company will need to educate primary care physicians and general cardiologists.</li><li>BTIG analyst Ryan Zimmerman keeps a ‘Neutral’ rating on Medtronic. BTIG said that while the news was expected, it is still a win for Medtronic. BTIG believes the decision opens up Medtronic to a "massive" potential patient pool.</li></ul>&nbsp;On Stocktwits, retail sentiment around Medtronic stayed within ‘neutral’ territory over the past 24 hours while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_at_1_28_21_PM_png_9314bf702a.webp" alt="MDT's Sentiment Meter and Message Volume as of 1:30 p.m. ET on July 11, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>MDT's Sentiment Meter and Message Volume as of 1:30 p.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure>MDT stock is up by nearly 13% this year and by over 15% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/cel-sci-to-sign-partnership-with-saudi-arabian-pharma-company-for-cancer-drug/ch8c1PLR5ZC">CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CMS’s Initial Proposal To Cover Renal Denervation A Win For Medtronic, Says Analysts

CMS is now seeking comments on its proposed decision, and a final decision is expected by October 8.

Health technology company Medtronic plc (MDT) on Tuesday announced the appointment of Chad Spooner as CFO of MiniMed.The appointment comes ahead of MiniMed’s separation from Medtronic as a standalone, public company. MDT shares are trading 1% higher at the time of writing.Medtronic announced its <a href="https://stocktwits.com/news-articles/markets/equity/medtronic-announes-split-of-diabetes-business/ch0ec0dRbYg">intent to split</a> its Diabetes business into a standalone company in May. The move, it said, will create a more focused Medtronic, with a more simplified portfolio including cardiovascular, neuroscience, and medical-surgical.The company also noted that the separation is expected to be accretive to Medtronic’s earnings and operating margin.<a href="https://stocktwits.com/symbol/MDT">Medtronic</a> expects the separation to be completed within 18 months of the initial announcement. The company is eyeing an initial public offering (IPO) and subsequent split-off.Que Dallara will be the CEO of the new diabetes company, named MiniMed, which is expected to have over 8,000 employees. Dallara is currently the President of Medtronic Diabetes.Spooner’s appointment will be effective July 14, and he will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives.He was most recently CFO at BIC, a publicly traded global consumer goods company. Dallara also held leadership roles across healthcare, consumer, and industrial sectors, including at Raffaela Apparel Group, Slingshot Health, and Tenex Capital Management.Medtronic’s diabetes portfolio reported revenue of $2.76 billion in fiscal year 2025 (FY25), marking a growth of 10.7% year-on-year (YoY) and representing 8% of Medtronic’s total revenue in the period.On Stocktwits, retail sentiment around Medtronic is trending in the ‘neutral’ territory over the past 24 hours, coupled with ‘high’ message volume.<figure class="image"><img style="aspect-ratio:1378/122;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_08_at_12_41_52_PM_png_5beb980fab.webp" alt="MDT's Sentiment Meter and Message Volume as of 12:40 p.m. ET on July 8, 2025 | Source: Stocktwits" width="1378" height="122"><figcaption>MDT's Sentiment Meter and Message Volume as of 12:40 p.m. ET on July 8, 2025 | Source: Stocktwits</figcaption></figure>MDT stock is up by 11% this year and by about 15% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-seeks-approval-for-higher-wegovy-dose-in-europe/chFvDEAR5Wj">Novo Nordisk Seeks Approval For Higher Wegovy Dose In Europe</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medtronic Names CFO For New Diabetes Company Ahead Of Intended Spin-Off

Chad Spooner’s appointment will be effective July 14, and he will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives.

Invesco Capital Management LLC - Invesco S&P 500 ex-Rate Sensitive Low Volatility ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

XRLV
Invesco S&P 500 ex-Rate Sensitive Low Volatility ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XRLV News

XRLVInvesco S&P 500 ex-Rate Sensitive Low Volatility ETF